Author： Gilbert Eric J
Publisher： Informa Healthcare
ISSN： 1354-3776
Source： Expert Opinion on Therapeutic Patents, Vol.23, Iss.8, 2013-08, pp. : 1069-1073
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
This patent review covers the contents of Hoffman-La Roche and Siena Biotech's patent application WO2012156284 titled `1,3-Oxazines as BACE1 and/or BACE2 Inhibitors.' Beta-site amyloid precursor protein-converting enzyme (BACE1) and BACE2 activities are reported to support the claimed compounds' use as therapeutics for Alzheimer's disease and type II diabetes, respectively. A common core motif of the claimed compounds is the six-membered 1,3-oxazine system. To gain access to the S3 and S3 subpocket of the BACE1 active site, various linkers are described including nitrogen- and oxygen-based, aryl, and amide-based linkers. Of the 65 compounds claimed, 6 had IC50s less than 100 nM in the BACE1 cell assay. Cellular BACE2 inhibition data are reported for 20 compounds with 2 under 100 nM.
Related content
Access to resources
Recommend
Development of BACE1 Inhibitors for Alzheimer's Disease
Current Medicinal Chemistry, Vol. 13, Iss. 15, 2006-06 ,pp. :
Computational Methods in the Discovery and Design of BACE-1 Inhibitors
Current Medicinal Chemistry, Vol. 19, Iss. 36, 2012-12 ,pp. :
Structure-Based &bgr;-Secretase (BACE1) Inhibitors
Current Pharmaceutical Design, Vol. 20, Iss. 20, 2014-05 ,pp. :